LSA

Discovery

Albert Hofmann, working at Sandoz Laboratories in Basel, isolated ergine from ololiuqui (Turbina corymbosa) seeds in 1960 — revealing for the first time that ergot alkaloids, previously known only from the fungal genus Claviceps, occurred in flowering plants.^[3] The active principle behind centuries of Mesoamerican ritual use was resolved as primarily ergine rather than a novel alkaloid class. Hofmann later described self-experiments with LSA, noting psychotomimetic properties at low milligram doses.^[8]

Cultural and scientific significance

The presence of ergot alkaloids in morning glory plants was a botanical puzzle until researchers demonstrated that Periglandula — a clavicipitaceous endophytic fungus — synthesizes the alkaloids in symbiosis with host plants, rather than the plants producing them independently.^[9] In 2026, experimental work provided the first chemical support for the long-standing hypothesis that the kykeon of ancient Greece's Eleusinian Mysteries was psychoactive due to ergot-derived LSA, showing that ergopeptides can be converted to ergine via alkaline treatment feasible with ancient technology.^[10]

Modern era

LSA gained visibility in the 2000s as a "legal high," with Hawaiian baby woodrose and morning glory seeds marketed through online vendors.^[11] French pharmacovigilance data recorded adverse events including hospitalizations,^[11] and a fatal case involving behavioral consequences of intoxication prompted forensic characterization.^[12] Survey data identified LSA among indoleamine hallucinogens used by cluster headache sufferers for prophylactic treatment,^[13] but no clinical trial has been registered to evaluate this or any other use.^[4]

Structural class

LSA belongs to the ergoline chemical class — tetracyclic compounds sharing the ergoline nucleus, a 6,6,6,5-fused ring system incorporating an indole moiety. The ergolines include LSD, ergotamine, and ergometrine, all derived from d-lysergic acid. LSA is the simplest amide of lysergic acid, bearing an unsubstituted primary carboxamide at C-9 where LSD carries a diethylamide group.^[14]

The C-9 amide substitution pattern critically determines potency at serotonin receptors: LSD's diethylamide confers approximately 10–25× greater potency at 5-HT₂A compared to LSA's unsubstituted amide.^[1] The 5-HT₂A receptor is less tolerant of long alkyl substituents on the amide nitrogen than 5-HT₁A, contributing to differences in selectivity across the lysergamide series.^[15]

Molecular properties

The ergoline nucleus comprises four fused rings: an indole ring (rings A and B), a partially saturated ring C, and a piperidine ring D. LSA retains the indole N-H and bears an N-methyl group on the piperidine nitrogen.^[16]

Stereochemistry

LSA possesses two stereocenters at C-6a and C-9. The pharmacologically active form adopts the (6aR,9R) configuration — the d-isomer (ergine). Its epimer isoergine (6aR,9S) has markedly reduced activity.^[14][15] Both epimers occur in plant material, though ergine predominates.^[7]

Physical properties

LSA is a white to off-white crystalline solid that fluoresces bluish-violet under ultraviolet light.^[17] It has no true melting point, darkening at approximately 200°C and decomposing at ~225°C. The compound is sensitive to light and heat, requiring dark, inert-atmosphere storage — a constraint that contributes to variable potency in seed preparations.

Natural occurrence

LSA is not synthesized by host plants but by Periglandula — a clavicipitaceous endophytic fungus living in obligate symbiosis with Convolvulaceae species.^[9] Principal LSA-containing species include:

• Turbina corymbosa (ololiuqui) — seeds used in Mesoamerican ritual
• Ipomoea violacea (morning glory)
• Argyreia nervosa (Hawaiian baby woodrose) — the most commonly consumed commercial source

Seeds also contain co-alkaloids including ergometrine (a potent uterotonic), lysergol, and chanoclavine.^[7]

Mechanism of action

LSA produces its psychoactive effects primarily through agonism at the serotonin 5-HT₂A receptor — the same target engaged by LSD, psilocin, and DMT.^[14][1] What distinguishes LSA from most classical psychedelics is its approximately threefold higher affinity for 5-HT₁A over 5-HT₂A,^[1] likely contributing to its more sedating, less visually elaborate character compared to LSD.

LSA functions as a partial agonist at serotonergic receptors.^[2] It also stimulates D2 dopamine receptors, an action specifically linked to the prominent nausea that accompanies its use.^[2] Broader lysergamide class data confirm binding at both D1-like and D2-like dopamine receptors.^[18]

The psychedelic mechanism is confirmed through behavioral studies: lysergamides produce LSD-like discriminative stimulus effects mediated through 5-HT₂A agonism, and the head twitch response in rodents — a standard proxy for psychedelic activity — is abolished by 5-HT₂A antagonism.^[14][19]

Pharmacokinetics

No controlled human pharmacokinetic study has been published for LSA. All available data derive from a single forensic case and structural analogy to LSD.

Onset of effects from seed ingestion occurs at 30–180 minutes, a wide range reflecting variable absorption affected by seed composition, stomach contents, and extraction method.^[4] No bioavailability, peak concentration, or time-to-peak data exist for purified LSA in humans.

A forensic analysis identified a hydroxylated metabolite of LSA in urine following fatal ingestion of Argyreia nervosa seeds.^[12] This metabolic transformation closely parallels a known LSD metabolite produced by liver enzymes,^[20] suggesting similar metabolic pathways.inferred

The only published human blood concentrations derive from a forensic case: 4.9 µg/L in a deceased individual and 1.8 µg/L in a survivor.^[12] Total duration of effects spans 4–10 hours, with residual effects persisting up to 24 hours.^[4] No half-life, protein binding, or clearance data have been published.

Where it acts

As a serotonin 2A receptor agonist, LSA is expected to engage the same neural circuits documented for LSD and psilocybin: disruption of the default mode network, reduced thalamocortical gating, increased global functional connectivity, and elevated neural entropy.^[14]inferred No direct neuroimaging data have been published for LSA.

The stronger 5-HT₁A component in LSA's profile introduces a modulatory variable. 5-HT₁A agonism on cortical neurons produces inhibitory effects that may partially counterbalance 5-HT₂A-mediated excitation,^[21] potentially explaining why the experience is reported as heavier and less visually stimulating than LSD. D2 dopamine receptor engagement may contribute to motor-sedative and emetic components.^[18][2]

Why it matters

The REBUS model proposes that psychedelics reduce the brain's reliance on prior expectations, allowing raw sensory information greater influence on conscious experience. LSA's confirmed 5-HT₂A agonism is consistent with this framework, though its stronger 5-HT₁A activity may limit the degree of this relaxation compared to more selective compounds.inferred

Whether LSA promotes structural neuroplasticity — the psychoplastogen hypothesis, in which psychedelics drive new neural connections via signaling cascades downstream of 5-HT₂A — is untested. Its partial agonist profile raises the question of whether it engages the same plasticity pathways as more potent agonists.

Toxicity

No lethal dose has been established for LSA in humans or animals.^[4] No specific organ toxicity has been characterized through controlled study.

The most severe documented complication is Posterior Reversible Encephalopathy Syndrome (PRES) with concurrent seizures, reported in one case.^[6] The proposed mechanism involves ergoline vasoconstriction causing acute blood pressure crisis leading to failure of the brain's blood flow regulation. This remains the only published case of LSA-induced PRES.

Psychological risks

Acute psychological distress, hallucinations, and impaired reality testing are documented.^[12][11] French pharmacovigilance data recorded 4 cases involving unintended psychological effects, with 2 requiring hospitalization.^[11]

Post-use suicidal ideation and psychosis-like states requiring hospitalization have been noted,^[2] though detailed case descriptions are limited and confounding variables (pre-existing conditions, polysubstance use) are not controlled for. No data exist on the prevalence of persistent perceptual changes or lasting psychosis following LSA use.

Tolerance & dependence

Classical psychedelics produce rapid tolerance through downregulation. Repeated dosing produces significant decreases in 5-HT₂A binding within days, with recovery within approximately 96 hours.^[22] Tolerance to psychedelic effects develops rapidly — including after single doses.^[5]

Cross-tolerance between psychedelics sharing the 5-HT₂A mechanism is established.^[5] LSA is expected to produce and be subject to cross-tolerance with LSD and other classical psychedelics.inferred

No dependence syndrome, compulsive use pattern, or physical withdrawal has been identified for LSA or any classical psychedelic. The rapid tolerance mechanism itself functions as a biological deterrent to frequent dosing.

Drug interactions

As a serotonin receptor agonist, combination with other serotonergic agents — MAOIs, SSRIs, SNRIs, tramadol — creates additive serotonergic burden that may precipitate serotonin syndrome.safety citation needed

The ergoline scaffold introduces a second risk dimension: vasoconstrictive synergy. Combination with triptans, ergotamine derivatives, or stimulants compounds vasoconstriction risk, potentially increasing the probability of blood pressure crisis or cerebrovascular events such as PRES.^[6]inferred

Lithium co-administration represents a theoretical risk shared across classical psychedelics: case reports associate lithium with seizures and prolonged psychotic episodes when combined with serotonergic psychedelics.safety citation needed

No published drug interaction study exists for LSA with any co-administered substance.

Contraindications

Absolute:

• Pregnancy and breastfeeding: Seeds contain ergometrine, a potent uterotonic that poses abortifacient risk. This applies specifically to seed-based preparations; purified LSA's reproductive toxicity is unevaluated.safety citation needed

Relative:

• High blood pressure and heart disease: Ergoline-class vasoconstriction documented via case reports.^[6]
• Cerebrovascular disease: PRES represents a direct complication from LSA's vasoconstrictive mechanism.
• Personal or family history of psychotic disorders: Class-level risk; psychosis-like states documented post-LSA use.^[2]
• Seizure disorders: The PRES case involved seizures, suggesting threshold lowering is possible.^[6]
• Concurrent serotonergic medication: Serotonin syndrome risk from combined serotonergic activity.

The legal status of LSA varies across jurisdictions, with a notable distinction in many countries between the controlled pure compound and the unscheduled plant materials (seeds) that contain it. This regulatory gap has facilitated the marketing of LSA-containing seeds as "legal highs".^[11]

The United States classification of LSA as a Schedule III "depressant" is a historical artifact that predates pharmacological characterization of its mechanism; the compound is pharmacologically a serotonergic psychedelic, not a CNS depressant.^[23]

Legal status data for Germany and most EU member states outside the Netherlands and Sweden could not be confirmed from official government or peer-reviewed sources. The Erowid database was used as a secondary source and may not reflect current legislation.citation needed